MDWD
MediWound Ltd.
NasdaqGMUSDEQUITY
DELAYED
Last price
13.21
▲ 0.10 (0.72%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
13.65
Prev close
13.12
Day high
13.32
Day low
13.07
Volume
78.92K
Market cap
—
P/E (TTM)
—
52W range
13.06 – 20.30
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
-2.58%
-1.2%
1M
-7.43%
-11.2%
3M
-21.56%
-24.7%
6M
-26.08%
-37.1%
YTD
-28.44%
-40.7%
1Y
-24.25%
-44.3%
3Y
+48.09%
-26.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $16.96M | $20.22M | $18.69M | $26.50M | -16.1% |
| Operating revenue | $16.96M | $20.22M | $18.69M | $26.50M | -16.1% |
| Cost of revenue | $13.71M | $17.59M | $15.11M | $13.33M | -22.1% |
| Gross profit | $3.25M | $2.63M | $3.58M | $13.16M | +23.5% |
| Research & development | $14.32M | $8.88M | $7.47M | $10.18M | +61.3% |
| Selling, general & admin | $13.93M | $12.91M | $11.38M | $10.37M | +7.9% |
| Total operating expense | $28.53M | $22.02M | $19.08M | $20.83M | +29.6% |
| Operating income | -$25.28M | -$19.38M | -$15.50M | -$7.66M | -30.4% |
| Net interest income | $816.00K | -$35.00K | $1.10M | -$2.26M | +2,431.4% |
| Pre-tax income | -$23.71M | -$30.16M | -$6.53M | -$19.52M | +21.4% |
| Tax provision | $169.00K | $61.00K | $185.00K | $78.00K | +177.0% |
| Net income | -$23.88M | -$30.22M | -$6.72M | -$19.60M | +21.0% |
| Net income to common | -$23.88M | -$30.22M | -$6.72M | -$19.60M | +21.0% |
| Basic EPS | -2.10 | -3.03 | -0.75 | -3.93 | +30.7% |
| Diluted EPS | -2.10 | -3.03 | -0.75 | -3.93 | +30.7% |
| EBIT | -$23.33M | -$29.41M | -$6.10M | -$19.52M | +20.7% |
| EBITDA | -$21.47M | -$27.93M | -$4.80M | -$18.25M | +23.1% |
| Basic shares | 11.38M | 9.96M | 9.01M | 4.99M | +14.2% |
| Diluted shares | 11.38M | 9.96M | 9.01M | 4.99M | +14.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $4.80M | $9.15M | $11.87M | $33.90M | -47.6% |
| Cash & short-term investments | $53.14M | $43.16M | $11.87M | $33.90M | +23.1% |
| Accounts receivable | $1.62M | $4.80M | $3.70M | $9.33M | -66.2% |
| Inventory | $4.09M | $2.69M | $2.85M | $1.96M | +52.0% |
| Total current assets | $59.96M | $52.16M | $49.70M | $45.84M | +15.0% |
| Property, plant & equipment | $25.79M | $20.80M | $15.93M | $3.58M | +24.0% |
| Goodwill & intangibles | $33.00K | $99.00K | $165.00K | $231.00K | -66.7% |
| Total assets | $86.25M | $73.50M | $66.46M | $50.02M | +17.4% |
| Total current liabilities | $25.71M | $26.54M | $18.13M | $12.06M | -3.1% |
| Total debt | $8.15M | $6.51M | $6.35M | $846.00K | +25.2% |
| Total liabilities | $42.62M | $42.34M | $34.86M | $39.10M | +0.7% |
| Retained earnings | -$228.93M | -$205.05M | -$174.82M | -$168.11M | -11.6% |
| Shareholder equity | $43.63M | $31.15M | $31.59M | $10.91M | +40.1% |
| Working capital | $34.26M | $25.62M | $31.57M | $33.78M | +33.7% |
| Net tangible assets | $43.60M | $31.05M | $31.43M | $10.68M | +40.4% |
| Shares issued | 12.84M | 10.79M | 9.22M | 7.24M | +18.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$23.88M | -$30.22M | -$6.72M | -$19.60M | +21.0% |
| Depreciation & amortisation | $1.86M | $1.48M | $1.30M | $1.27M | +25.4% |
| Stock-based compensation | $3.11M | $3.14M | $1.94M | $1.95M | -1.0% |
| Change in working capital | $4.77M | $1.27M | $2.34M | -$7.24M | +275.4% |
| Operating cash flow | -$16.12M | -$13.62M | -$10.46M | -$11.88M | -18.3% |
| Capital expenditure | -$5.50M | -$6.27M | -$6.46M | -$555.00K | +12.2% |
| Investing cash flow | -$17.95M | -$8.40M | -$34.32M | -$481.00K | -113.8% |
| Financing cash flow | $29.62M | $19.39M | $22.92M | $35.76M | +52.7% |
| Free cash flow | -$21.63M | -$19.90M | -$16.93M | -$12.44M | -8.7% |
| End cash position | $4.80M | $9.15M | $11.87M | $33.90M | -47.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.48M | $1.87M | $5.43M | $5.71M | $3.96M | -21.0% |
| Operating revenue | $1.48M | $1.87M | $5.43M | $5.71M | $3.96M | -21.0% |
| Cost of revenue | $1.15M | $1.59M | $4.53M | $4.37M | $3.22M | -27.5% |
| Gross profit | $323.00K | $278.00K | $896.00K | $1.34M | $738.00K | +16.2% |
| Research & development | $5.18M | $4.48M | $3.46M | $3.49M | $2.89M | +15.8% |
| Selling, general & admin | $3.56M | $3.33M | $3.96M | $3.57M | $3.07M | +6.8% |
| Total operating expense | $8.30M | $8.09M | $7.42M | $7.06M | $5.96M | +2.6% |
| Operating income | -$7.98M | -$7.81M | -$6.53M | -$5.72M | -$5.22M | -2.1% |
| Net interest income | $5.01M | -$50.00K | $3.93M | -$7.56M | $4.50M | +10,122.0% |
| Pre-tax income | -$2.97M | -$7.11M | -$2.60M | -$13.28M | -$721.00K | +58.2% |
| Tax provision | -$17.00K | $73.00K | $53.00K | $38.00K | $5.00K | -123.3% |
| Net income | -$2.95M | -$7.18M | -$2.65M | -$13.32M | -$726.00K | +58.9% |
| Net income to common | -$2.95M | -$7.18M | -$2.65M | -$13.32M | -$726.00K | +58.9% |
| Basic EPS | -0.23 | -0.56 | -0.24 | -1.23 | -0.07 | +58.9% |
| Diluted EPS | -0.23 | -0.56 | -0.24 | -1.23 | -0.07 | +58.9% |
| EBIT | -$7.98M | -$5.86M | -$6.53M | -$5.72M | -$5.22M | -36.1% |
| EBITDA | -$7.60M | -$5.17M | -$6.11M | -$5.32M | -$4.87M | -46.9% |
| Basic shares | 12.87M | 12.83M | 11.02M | 10.84M | 10.80M | +0.4% |
| Diluted shares | 12.87M | 12.83M | 11.02M | 10.84M | 10.80M | +0.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | $4.80M | — | — | — | $9.15M | — |
| Cash & short-term investments | $44.65M | $53.14M | $59.09M | $32.44M | $38.27M | — | -16.0% |
| Accounts receivable | $2.75M | $1.62M | $6.04M | $6.80M | $5.18M | — | +69.5% |
| Inventory | $4.77M | $4.09M | $4.41M | $3.84M | $3.58M | — | +16.6% |
| Total current assets | $52.17M | $59.96M | $69.53M | $43.08M | $47.02M | — | -13.0% |
| Property, plant & equipment | $27.33M | $25.79M | $24.38M | $23.37M | $21.43M | — | +6.0% |
| Goodwill & intangibles | $17.00K | $33.00K | $50.00K | $66.00K | $83.00K | — | -48.5% |
| Total assets | $79.98M | $86.25M | $94.42M | $67.00M | $69.02M | — | -7.3% |
| Total current liabilities | $21.65M | $25.71M | $26.25M | $29.07M | $21.84M | — | -15.8% |
| Total debt | $8.13M | $8.15M | $8.27M | $8.07M | $6.42M | — | -0.3% |
| Total liabilities | $38.56M | $42.62M | $44.27M | $46.88M | $37.74M | — | -9.5% |
| Retained earnings | — | -$228.93M | — | — | — | -$205.05M | — |
| Shareholder equity | $41.42M | $43.63M | $50.16M | $20.12M | $31.27M | — | -5.1% |
| Working capital | $30.52M | $34.26M | $43.28M | $14.01M | $25.18M | — | -10.9% |
| Net tangible assets | $41.41M | $43.60M | $50.11M | $20.05M | $31.19M | — | -5.0% |
| Shares issued | 12.85M | 12.84M | 12.82M | 10.88M | 10.81M | — | +0.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$2.95M | -$7.18M | -$2.65M | -$13.32M | -$726.00K | +58.9% |
| Depreciation & amortisation | $378.00K | $690.00K | $418.00K | $394.00K | $358.00K | -45.2% |
| Stock-based compensation | $644.00K | $662.00K | $740.00K | $862.00K | $844.00K | -2.7% |
| Change in working capital | $756.00K | $3.63M | $2.30M | -$1.10M | -$62.00K | -79.1% |
| Operating cash flow | -$6.75M | -$3.02M | -$3.24M | -$5.76M | -$4.11M | -123.9% |
| Capital expenditure | -$1.82M | -$2.45M | -$1.04M | -$1.05M | -$959.00K | +25.8% |
| Investing cash flow | $17.76M | -$23.89M | $4.38M | $4.91M | -$3.34M | +174.3% |
| Financing cash flow | -$421.00K | -$1.09M | $30.52M | $549.00K | -$362.00K | +61.4% |
| Free cash flow | -$8.57M | -$5.47M | -$4.28M | -$6.80M | -$5.07M | -56.8% |
| End cash position | $15.35M | $4.80M | $32.74M | $1.06M | $1.36M | +219.9% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
13.57
-2.66% from price
SMA 20
13.94
-5.21% from price
SMA 50
14.25
-7.32% from price
SMA 100
15.26
-13.44% from price
SMA 200
16.51
-19.98% from price
EMA 12
13.63
-3.05% from price
EMA 26
13.93
-5.19% from price
EMA 50
14.32
-7.77% from price
RSI (14)
34.9
Neutral
MACD (12,26,9)
-0.31
Hist -0.07
ATR (14)
0.44
3.36% of price
Realised vol 30D
24.1%
Annualised
Bollinger upper
14.78
20, 2σ
Bollinger lower
13.09
20, 2σ
50 / 200 cross
Death
14.25 vs 16.51
Trend bias
Below 200
-19.98%
Risk profile
Beta vs SPY
0.71
Less volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
24.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-33.4%
Peak to trough
Max drawdown 5Y
-74.4%
Peak to trough
ATR 14
0.44
3.36% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
MediWound (MDWD) Q2 2026 Earnings Call Transcript
Motley Fool · 2d ago
Oppenheimer Adjusts Price Target on MediWound to $30 From $32, Keeps Outperform Rating
MT Newswires · 8d ago
MediWound Ltd. Q2 2026 Earnings Call Summary
Moby · 8d ago
MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record NexoBrid Sales and EscharEx ...
GuruFocus.com · 9d ago
MediWound Q2 Earnings Call Highlights
MarketBeat · 9d ago
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
Zacks · 10d ago
MediWound: Q2 Earnings Snapshot
Associated Press · 10d ago
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewswire · 10d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.